Julie & Holleman LLP, a top-tier stockholder rights firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) and its executives for recent losses suffered by the company's stockholders.
Additional Information
According to a complaint recently filed in federal court, Iovance and its executives misled investors by exaggerating the company's financial prospects and downplaying risk factors affecting the company's growth potential. Among other things, the complaint alleges that the company concealed that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars in prior cases, is investigating legal claims against Iovance, its executives, and potentially also the company's board of directors.